Chemed Q4 revenue up 7.2% to $585.9M; VITAS adjusted EBITDA +61.6%; FY2024 guidance issued

CHEMED CORP

2023-FY EPS reported $17.93 revenue$2,264,417,000

GAAP diluted EPS $5.90 (+42.9% YoY); adjusted diluted EPS $6.60 (+35.0% YoY).
VITAS net patient revenue $350M (+13.6%), ADC 19,352 (+11%), adjusted EBITDA excl. Medicare Cap $83.3M (+61.6%), margin 23.7%.
Roto-Rooter revenue $235.9M (-1.1%), adjusted EBITDA $64.9M (-6.4%), margin 27.5% (down 154 bps).
FY2024 adj. EPS guidance $23.30-$23.70 vs 2023 adj. EPS $20.30; VITAS rev growth 9-9.8%, Roto-Rooter rev growth 3.5-4%.
Cash $264M, no debt; repurchased 79,512 shares for $46M at $579.09 per share.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CHEMED CORP reported the quarter ended December 31, 2023 results: revenue $585.9 million, EPS $5.90.

Period: the quarter ended December 31, 2023
Revenue: $585.9 million
EPS: $5.90
Result: reported results

Exact text from the filing

Retention Program was $19.6 million and $14.6 million, respectively. Results for Quarter Ended December 31, 2023 Consolidated operating results: · Revenue increased 7.2% to $585.9 million · GAAP Diluted Earnings-per-Share (EPS) of $5.90, an increase of 42.9% · Adjusted Diluted EPS of $6.60, an increase of 35.0% VITAS segment operating results: · Net Patient

View on SEC.gov

Browse all earnings releases →

CHEMED CORP filing history →

Source: SEC EDGAR

accession 0001562762-24-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.